Skip to main content

Table 3 OPA responses against individual pneumococcal vaccine serotypes and cross-reactive serotypes 6A and 19A 1 month after 3-dose primary vaccination (ATP immunogenicity cohort)

From: Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial

  PHiD-CV group Control group
PHiD-CV serotypes N % ≥ 8 (95% CI) GMT (95% CI) N % ≥ 8 (95% CI) GMT (95% CI)
1 105 87.6 (79.8-93.2) 83.0 (61.7-111.7) 56 5.4 (1.1-14.9) 5.0 (3.8-6.4)
4 105 100 (96.5-100) 892.5 (759.4-1049.0) 55 5.5 (1.1-15.1) 4.6 (3.9-5.5)
5 105 95.2 (89.2-98.4) 82.7 (65.4-104.4) 56 3.6 (0.4-12.3) 4.5 (3.8-5.2)
6B 103 85.4 (77.1-91.6) 538.6 (346.0-838.3) 54 9.3 (3.1-20.3) 5.7 (4.1-7.9)
7F 105 100 (96.5-100) 2733.0 (2188.3-3413.3) 49 42.9 (28.8-57.8) 31.5 (15.5-64.0)
9V 105 98.1 (93.3-99.8) 1023.7 (784.8-1335.2) 54 24.1 (13.5-37.6) 8.4 (5.8-12.4)
14 104 96.2 (90.4-98.9) 1079.2 (776.0-1500.9) 53 24.5 (13.8-38.3) 8.9 (5.7-14.1)
18C 105 98.1 (93.3-99.8) 617.6 (495.3-770.0) 56 3.6 (0.4-12.3) 4.4 (3.8-5.2)
19F 105 96.2 (90.5-99.0) 358.3 (269.9-475.5) 56 3.6 (0.4-12.3) 4.6 (3.8-5.7)
23F 104 93.3 (86.6-97.3) 881.8 (615.0-1264.4) 53 9.4 (3.1-20.7) 6.6 (4.2-10.3)
Cross-reactive serotypes
6A 101 30.7 (21.9-40.7) 14.1 (9.4-21.2) 56 10.7 (4.0-21.9) 6.1 (4.4-8.7)
19A 105 37.1 (27.9-47.1) 11.0 (8.3-14.6) 56 5.4 (1.1-14.9) 4.3 (4.0-4.6)
  1. NOTE. GMT, geometric mean titre; N, number of subjects with available results.